Surgerii Robotics is a Chinese surgical robotics manufacturer focused on single-port endoscopic surgery, a demanding approach in which an entire robotic procedure is performed through one small access point rather than multiple incisions. Its flagship SHURUI single-port surgical robot is built around a proprietary dual continuum mechanism, a flexible, snake-like instrument architecture that gives surgeons dexterity and reach inside the body while minimizing trauma to the patient.
The company, formally Beijing Surgerii Robotics Company Limited, was founded on technology developed by Dr. Kai Xu, a full professor at Shanghai Jiao Tong University, under the university's technology transfer policy. The dual continuum mechanism at the core of the SHURUI SP system reflects years of academic research into continuum robotics, translated into a clinical platform intended to expand the range of procedures achievable through single-port access.
The SHURUI robot is designed for use across urologic, gynecologic, general, and thoracoscopic procedures in both adult and pediatric patients, a notably broad indication set for a single-port system. By concentrating instrument access through one port, the approach aims to reduce scarring, pain, and recovery time compared with multi-port laparoscopic or open surgery, while preserving the precision and control of robotic assistance.
Surgerii Robotics closed a $100 million Series D financing round announced in early 2026, led by Loyal Valley Capital, with participation from Shanghai Healthcare Capital, V Star Capital, DNV Capital, and Hefei Industrial Investment. Having secured Europe's CE mark for its single-port system, the company is using the capital to accelerate global commercialization and clinical adoption of SHURUI and to develop next-generation products. Surgerii is headquartered in Beijing, China.